Rowena Albanna Form 3 ADiTx Therapeutics / Rowena Albanna ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Albanna Rowena

(Last) (First) (Middle)

C/O ADITX THERAPEUTICS, INC.

11161 ANDERSON STREET, SUITE 105-10014

(Street)

LOMA LINDA CA 92354

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/10/2020

3. Issuer Name and Ticker or Trading Symbol
ADiTx Therapeutics, Inc. [ ADTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CHIEF OPERATING OFFICER

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	35,555	D
Common Stock	438,055	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	10/05/2027	Common Stock	200,000	4	D
Stock Option (Right to Buy)	(3)	10/05/2027	Common Stock	600,000	4	I	See Footnote(1)
Series A Warrant	07/02/2020	06/29/2025	Common Stock	35,555	9	D
Series A Warrant	07/02/2020	06/29/2025	Common Stock	38,055	9	I	See Footnote(1)
Series B Warrant	07/02/2020	06/29/2025	Common Stock	35,555	11.25	D
Series B Warrant	07/02/2020	06/29/2025	Common Stock	38,055	11.25	I	See Footnote(1)

Explanation of Responses:

1. Held beneficially by the husband of the Reporting Person.

2. 50,000 of the options became exercisable on February 9, 2018 and 150,000 of the options became exercisable on April 17, 2019.

3. 200,000 of the options became exercisable on March 6, 2018 and 400,000 of the options became exercisable on April 17, 2019.

	/s/ Rowena Albanna	07/20/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.